In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Meta-analysis on MitraClip implantation for functional mitral regurgitation

Session Poster Session 4

Speaker Assistant Professor Michel Noutsias

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Multidisciplinary Interventions
  • Session type : Poster Session

Authors : M Noutsias (Halle,DE), M Matiakis (Halle,DE), M Ali (Halle,DE), E Abate (Halle,DE), H Melnyk (Halle,DE), B Bigalke (Berlin,DE), AG Rigopoulos (Halle,DE)

M Noutsias1 , M Matiakis1 , M Ali1 , E Abate1 , H Melnyk1 , B Bigalke2 , AG Rigopoulos1 , 1University Clinic Halle (Saale), Mid-German Heart Center, Department of Internal Medicine III (KIM-III), Division of Cardiology - Halle - Germany , 2Charite - Campus Benjamin Franklin - Berlin - Germany ,


In patients with heart failure reduced left ventricular ejection fraction (HFrEF), moderate-to-severe or severe functional mitral regurgitation (FMR) may is associated with high rate of hospitalizations for heart failure and with increased mortality. Transcatheter mitral valve repair (TMVR) by MitraClip® implantation may effectively reduce severe MR; however, the long-term clinical effects of this procedure are not well defined.

Aims: We analyzed outcomes for rehospitalization and survival in heart failure patients with moderate-to-severe or severe functional mitral regurgitation (FMR) treated by either medical treatment (MT) only versus transcatheter mitral valve repair (TMVR) by MitraClip® implantation + MT by meta-analysis.

Methods & Results: By systematic search of bibliographic databases, we evaluated publications comparing heart failure patients with FMR treated by MT only versus treatment by MT combined with TMVR (by Mitraclip® implantation). Studies with a minimum of 25 enrolled patients and a follow/up period of at least 12 months were deemed eligible for this meta-analysis. We identified n=8 studies enrolling 2,960 HFrEF patients, divided into two study arms: MTVR by MitraClip® implantation and MT (n=1,692), versus FMR patients receiving MT only (n=1,268). At 12 months, there was a significant reduction in all-cause mortality favoring TMVR+MT (OR: 0.67; CI 95% 0.55-0.81), as well as a reduction of unplanned rehospitalizations (OR: 0.64; 95%; CI 0.54-0.77), compared with the MT only patients. At 24 months, there was a significant reduction of all-cause mortality in the TMVR+MT patient group (OR: 0.50; CI: 95%: 0.38-0.66; p<0.001). TMVR+MT was associated with significantly lower rates of unplanned re-admissions for heart failure compared with MT only at 12 months (OR: 0.69; 95% CI: 0.53-0.89; p<0.001) and at 24 months (OR: 0.53; 95% CI: 0.39-0.71; p<0.001).

Conclusions: This meta-analysis on n=2,960 patients with moderate-to-severe or severe FMR reveals that TMVR+MT, as compared with MT alone, is associated with a significant reduction of rehospitalizations and improvement of survival. These data imply additional evidence for TMVR by Mitraclip® in eligible heart failure patients with relevant FMR, which might be important for an update of the corresponding guidelines.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are